Spring Bank is devoted to pioneering its revolutionary SMNH chemistry platform to discover and develop a new generation of medicines to improve the lives of patients worldwide.

Inarigivir is being developed as a simple, safe and selective oral immunomodulator for inclusion in a combinatorial treatment of hepatitis B.

Our proprietary small molecule nucleic acid hybrids (SMNH) chemistry platform produces a class of compounds designed to selectively target and modulate the activity of specific proteins implicated in various disease states.